AMSilk, the Bavarian biotech producing advanced biomaterials from silk proteins, has raised €52M in fresh financing.
The round combines €30M in equity and €22M in convertible bonds, led by ATHOS (AT Newtec), with participation from MIG Capital and Novo Holdings.
Moving from lab to industrial scale
Founded in 2008, AMSilk has developed a microbial fermentation process that programs microorganisms to produce silk proteins. These can be processed into powders, gels, fibres, and coatings that are 100% protein-based, biodegradable, and free of microplastics.
Applications already span textiles, automotive components, and consumer care products. Multi-year supply agreements with partners such as Evonik and Ajinomoto signal strong commercial demand, with dedicated facilities now in place to deliver multi-ton production volumes.
Advertisement
Investors back industrial readiness
“AMSilk’s transition to full-scale production signals strong commercial validation,” said Daniel Kolb, Investment Manager at ATHOS. “The ability to manufacture biofabricated materials at multi-ton volumes confirms its industrial viability and readiness to meet growing market demand.”
Ralph Fraundorfer, CFO of AMSilk, added:
“As we move to industrial-scale production, we are focused on building robust processes and resilient supply chains — providing proof of our ability to deliver innovative biomaterials at scale.”
Toward a new materials industry
The company positions itself as a leader in biofabricated proteins, aiming to build a European-based supply chain for sustainable high-performance materials. The company says its silk-protein platform can be extended to multiple industries, from fashion to automotive and healthcare, supporting the shift to greener, circular alternatives.
Dr. Wolfgang Colberg, Chairman of AMSilk’s Advisory Board, summed it up:
“With this committed funding, we can massively scale-up production. This is a significant step toward establishing a new global industry for high-performance biotech materials.”
